Dimensional Fund Advisors LP Purchases 79,092 Shares of Maximus, Inc. (NYSE:MMS)
Dimensional Fund Advisors LP grew its position in Maximus, Inc. (NYSE:MMS – Free Report) by 7.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,153,977 shares of the…
Dimensional Fund Advisors LP Purchases 79,092 Shares of Maximus, Inc. (NYSE:MMS)
Dimensional Fund Advisors LP grew its position in Maximus, Inc. (NYSE:MMS – Free Report) by 7.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,153,977 shares of the health services provider’s stock after acquiring an additional 79,092 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Maximus were worth $98,904,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in MMS. Norges Bank bought a new stake in Maximus in the fourth quarter worth about $55,821,000. UBS Group AG lifted its stake in shares of Maximus by 60.7% during the 4th quarter. UBS Group AG now owns 72,724 shares of the health services provider’s stock worth $6,099,000 after acquiring an additional 27,466 shares during the last quarter. Coldstream Capital Management Inc. purchased a new position in Maximus during the 4th quarter valued at $210,000. Trexquant Investment LP bought a new position in Maximus in the 4th quarter valued at $1,222,000. Finally, US Bancorp DE increased its stake in Maximus by 20.3% in the fourth quarter. US Bancorp DE now owns 9,843 shares of the health services provider’s stock worth $825,000 after purchasing an additional 1,664 shares during the period. 97.21% of the stock is owned by hedge funds and other institutional investors.
Maximus Stock Up 1.3 %
Shares of MMS opened at $91.77 on Wednesday. The firm has a fifty day moving average price of $89.82 and a 200-day moving average price of $86.23. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $5.58 billion, a P/E ratio of 24.09 and a beta of 0.76. Maximus, Inc. has a 12-month low of $72.39 and a 12-month high of $93.97.
Maximus (NYSE:MMS – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The health services provider reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.27. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. Maximus had a net margin of 5.59% and a return on equity of 20.91%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.78 EPS. Equities research analysts expect that Maximus, Inc. will post 6.12 earnings per share for the current year.
Maximus Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Saturday, August 31st. Shareholders of record on Thursday, August 15th were issued a dividend of $0.30 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $1.20 annualized dividend and a yield of 1.31%. Maximus’s payout ratio is currently 31.50%.
About Maximus
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
Featured Articles
- Five stocks we like better than Maximus
- How to Use Stock Screeners to Find Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What is a support level?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Stock Market Sectors: What Are They and How Many Are There?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Want to see what other hedge funds are holding MMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maximus, Inc. (NYSE:MMS – Free Report).
Receive News & Ratings for Maximus Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Maximus and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: ETF Daily News